GlassScriptPhysician profile
Bethany Robbins
NPI 1376137547
$926.25
in general payments reported to CMS, 2019-2025
23 companies · $152 in 2025
The $152 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $388 · 2024: $385 · 2025: $152.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $926.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $926.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $139.42 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Orthofix Medical, INC. | $117.62 | 2024-2025 | Physio-Stim |
| Janssen Pharmaceuticals, INC | $83.07 | 2023-2024 | Spravato, Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $79.07 | 2023-2024 | Trulance, Xifaxan |
| Amgen INC. | $78.12 | 2023-2024 | Repatha, Otezla |
| Takeda Pharmaceuticals U.S.A., INC. | $49.80 | 2023-2024 | Trintellix |
| Ironshore Pharmaceuticals INC. | $42.25 | 2023-2024 | Jornay Pm |
| Harmony Biosciences LLC | $36.73 | 2024 | |
| Halozyme INC | $31.02 | 2023 | |
| Solventum Corporation | $30.17 | 2025 | Prevena |
| Astrazeneca Pharmaceuticals LP | $27.37 | 2024 | Flumist Quadrivalent |
| Novo Nordisk INC | $27.18 | 2024 | Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $23.24 | 2024 | Tradjenta, Synjardy, Jardiance |
| Sobi, INC | $20.32 | 2023 | |
| Merck Sharp & Dohme LLC | $19.84 | 2024 | Gardasil 9, Rotateq, Gardasil |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $17.87 | 2025 | |
| Axsome Therapeutics, INC. | $17.83 | 2023 | Auvelity |
| Pfizer INC. | $17.13 | 2024 | |
| Glaxosmithkline, LLC. | $15.49 | 2025 | Arexvy, Shingrix |
| Daiichi Sankyo INC. | $14.21 | 2023 | Injectafer |
| Antares Pharma, INC. | $13.61 | 2023 | Tlando, Xyosted, Nocdurna |
| Dynavax Technologies Corporation | $12.50 | 2023 | Heplisav-B |
| Corium, LLC | $12.39 | 2023 | Azstarys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bethany Robbins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.